These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 37140823)
21. Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia. Dong L; Xu W; Deng Y; Tan J; Qin W Eur J Pharmacol; 2022 Sep; 931():175174. PubMed ID: 35964658 [TBL] [Abstract][Full Text] [Related]
22. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials. Gruver J; Al-Makki A; Shepler B J Pharm Pharm Sci; 2023; 26():11892. PubMed ID: 38173862 [TBL] [Abstract][Full Text] [Related]
24. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592 [TBL] [Abstract][Full Text] [Related]
25. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors. Tamargo J; Caballero R; Delpón E Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448 [TBL] [Abstract][Full Text] [Related]
26. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis. Palmer BF Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450 [TBL] [Abstract][Full Text] [Related]
27. Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia. Rydell A; Thackrey C; Molki M; Mullins BP Ann Pharmacother; 2024 Aug; 58(8):790-795. PubMed ID: 37953506 [TBL] [Abstract][Full Text] [Related]
28. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Buysse JM; Huang IZ; Pitt B Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443 [TBL] [Abstract][Full Text] [Related]
29. Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study. Dwyer JP; Agiro A; Desai P; Oluwatosin Y Adv Ther; 2023 Nov; 40(11):4777-4791. PubMed ID: 37606716 [TBL] [Abstract][Full Text] [Related]
30. Patiromer: a clinical review. Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884 [TBL] [Abstract][Full Text] [Related]
31. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL Circulation; 2022 May; 145(19):1460-1470. PubMed ID: 35394821 [TBL] [Abstract][Full Text] [Related]
32. Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia. Cases A; Gorriz JL Drugs Today (Barc); 2018 Oct; 54(10):601-613. PubMed ID: 30398481 [TBL] [Abstract][Full Text] [Related]
33. Combination Therapy Using Sodium Zirconium Cyclosilicate and a Mineralocorticoid Receptor Antagonist in Patients with Heart Failure and Hyperkalemia. Imamura T; Oshima A; Narang N; Ushijima R; Ueno Y; Ueno H; Kinugawa K Intern Med; 2021; 60(13):2093-2095. PubMed ID: 34193775 [TBL] [Abstract][Full Text] [Related]
34. Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate Versus Patiromer. Zhuo M; Kim SC; Patorno E; Paik JM J Card Fail; 2022 Sep; 28(9):1414-1423. PubMed ID: 35470055 [TBL] [Abstract][Full Text] [Related]
35. Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Le HH; El-Khatib C; Mombled M; Guitarian F; Al-Gobari M; Fall M; Janiaud P; Marchant I; Cucherat M; Bejan-Angoulvant T; Gueyffier F PLoS One; 2016; 11(2):e0145958. PubMed ID: 26891235 [TBL] [Abstract][Full Text] [Related]
36. Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives. Llubani R; Vukadinović D; Werner C; Marx N; Zewinger S; Böhm M Curr Heart Fail Rep; 2018 Dec; 15(6):390-397. PubMed ID: 30421355 [TBL] [Abstract][Full Text] [Related]
37. Updates on medical management of hyperkalemia. Lopes MB; Rocha PN; Pecoits-Filho R Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):417-423. PubMed ID: 31268919 [TBL] [Abstract][Full Text] [Related]
38. The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease. Tamargo J; Caballero R; Delpón E Expert Opin Pharmacother; 2021 Jul; 22(10):1319-1341. PubMed ID: 33620275 [No Abstract] [Full Text] [Related]
39. Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options. Morales E; Cravedi P; Manrique J Front Med (Lausanne); 2021; 8():653634. PubMed ID: 34150795 [TBL] [Abstract][Full Text] [Related]
40. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]